TAK icon

Takeda Pharmaceutical

15.34 USD
-0.08
0.52%
At close Jul 3, 4:00 PM EDT
1 day
-0.52%
5 days
1.05%
1 month
2.47%
3 months
0.99%
6 months
15.69%
Year to date
15.77%
1 year
17.01%
5 years
-13.14%
10 years
-7.81%
 

About: Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Employees: 47,455

0
Funds holding %
of 7,310 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

3,914% more call options, than puts

Call options by funds: $25.9M | Put options by funds: $646K

51% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 35

23% more repeat investments, than reductions

Existing positions increased: 111 | Existing positions reduced: 90

11% more capital invested

Capital invested by funds: $954M [Q4 2024] → $1.06B (+$103M) [Q1 2025]

2% more funds holding

Funds holding: 294 [Q4 2024] → 300 (+6) [Q1 2025]

0.06% less ownership

Funds ownership: 4.53% [Q4 2024] → 4.47% (-0.06%) [Q1 2025]

Research analyst outlook

We haven’t received any recent analyst ratings for TAK.

Financial journalist opinion

Based on 3 articles about TAK published over the past 30 days

Neutral
Business Wire
6 days ago
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for people two years of age and older with primary immunodeficiency (PI). As a ready-to-use liquid, GAMMAGARD.
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Positive
Zacks Investment Research
1 week ago
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Neutral
Business Wire
1 week ago
Takeda Announces New Assignments of Directors
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, t.
Takeda Announces New Assignments of Directors
Neutral
Business Wire
1 month ago
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone (ECADD) – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April.
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
Neutral
Business Wire
1 month ago
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61st American Society of Clinical Oncology (ASCO) Annual Meeti.
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Neutral
Business Wire
1 month ago
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applications are now open for the Takeda Innovators in Science Award with Nature recognizing the groundbreaking research of early-career scientists.
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
Neutral
Business Wire
1 month ago
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measure.
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Positive
Seeking Alpha
1 month ago
Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise
Takeda Pharmaceuticals showed strong revenue and operating income growth in FY2024, despite challenges from Vyvanse generics and US insurance issues. New guidance for FY2025 is slightly lower due to expected deeper cuts from Vyvanse generics, but potential exists for surpassing this with new drug approvals. The dividend yield for FY2025 is projected at 4.81%, making Takeda an attractive option for income portfolios despite US healthcare market challenges.
Takeda Pharmaceuticals Caps A Strong Year, Guidance Suggests Dividend Is On The Rise
Positive
Zacks Investment Research
1 month ago
Top 4 GARP Stocks With Attractive PEG Ratios to Watch
Here we present four high-growth GARP picks based on discounted PEG. These are PAK, FIVN, LTM and MFG.
Top 4 GARP Stocks With Attractive PEG Ratios to Watch
Neutral
Seeking Alpha
1 month ago
Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript
Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q4 2024 Results Conference Call May 8, 2025 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President & Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Julie Kim - President of the U.S. Business Unit & U.S. Country Head Giles Platford - President of the Plasma-Derived Therapies Business Unit Conference Call Participants Hidemaru Yamaguchi - Citi Shinichiro Muraoka - Morgan Stanley Stephen Barker - Jefferies Mike Nedelcovych - TD Cowen Hiroyuki Matsubara - Nomura Securities Seiji Wakao - J.P. Morgan Tony Ren - Macquarie Akinori Ueda - Goldman Sachs Fumiyoshi Sakai - UBS Christopher O'Reilly Thank you very much for taking time out of their busy schedule to join our earnings announcement for FY '24 for Takeda.
Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript
Charts implemented using Lightweight Charts™